GI Innovation
GI Innovation is committed to developing innovative biopharmaceuticals for patients worldwide, focusing on immuno-oncology, allergy treatments, and metabolic diseases, utilizing its proprietary GI-SMART™ platform and a team of experts in scientific research. The company emphasizes transparent and ethical management, aiming to lead in global biopharmaceutical development.
Industries
Nr. of Employees
medium (51-250)
GI Innovation
Room 1116 of A-dong, Songpa-daero 167, Songpa-gu, Seoul (Munjeong-dong, Munjeong Station Terra Tower)
Patents
Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof
US-12128076-B2
View DetailsPharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
US-11857601-B2
View DetailsPharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain
US-11639383-B2
View Details
Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof
US-12128076-B2
View DetailsPharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
US-11857601-B2
View DetailsPharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain
US-11639383-B2
View DetailsProducts
CD80-targeted IL-2 variant fusion protein (clinical-stage immunocytokine)
A fusion protein comprising a CD80-targeting moiety fused to an IL-2 variant designed to direct immune activation; progressed through first-in-human and Phase 1/2a clinical studies.
Anti-CD73 / IL-2 variant bispecific fusion protein (early clinical)
A bispecific fusion protein combining a modality targeting CD73 with an IL-2 variant to reduce immunosuppression and enhance antitumor T cell responses; in early clinical evaluation.
IgE-targeting long-acting fusion protein for allergic disease (composition-patented)
A long-acting IgE-targeting fusion protein developed for IgE-mediated allergic diseases with composition and sialic-acid–based quality attributes protected by material patents; progressed through early clinical stages and subject to regional licensing.
Microbiome-based synbiotic program (collaborative)
A synbiotic combining selected probiotic strains with complementary ingredients to modulate gut microbiota; evaluated in elderly volunteers and animal aging models to support translational endpoints.
CD80-targeted IL-2 variant fusion protein (clinical-stage immunocytokine)
A fusion protein comprising a CD80-targeting moiety fused to an IL-2 variant designed to direct immune activation; progressed through first-in-human and Phase 1/2a clinical studies.
Anti-CD73 / IL-2 variant bispecific fusion protein (early clinical)
A bispecific fusion protein combining a modality targeting CD73 with an IL-2 variant to reduce immunosuppression and enhance antitumor T cell responses; in early clinical evaluation.
IgE-targeting long-acting fusion protein for allergic disease (composition-patented)
A long-acting IgE-targeting fusion protein developed for IgE-mediated allergic diseases with composition and sialic-acid–based quality attributes protected by material patents; progressed through early clinical stages and subject to regional licensing.
Microbiome-based synbiotic program (collaborative)
A synbiotic combining selected probiotic strains with complementary ingredients to modulate gut microbiota; evaluated in elderly volunteers and animal aging models to support translational endpoints.
Services
Collaborative design and execution of clinical combination studies and supply arrangements with external partners to enable multicenter trials and partner-agent provisioning.
Structuring and executing licensing deals and indication-based out-licensing strategies for therapeutic assets.
Joint preclinical studies to evaluate combination regimens and generate translational efficacy data for clinical translation.
Translational biomarker assay development and profiling conducted with instrumentation partners to support clinical and preclinical programs.
Collaborative design and execution of clinical combination studies and supply arrangements with external partners to enable multicenter trials and partner-agent provisioning.
Structuring and executing licensing deals and indication-based out-licensing strategies for therapeutic assets.
Joint preclinical studies to evaluate combination regimens and generate translational efficacy data for clinical translation.
Translational biomarker assay development and profiling conducted with instrumentation partners to support clinical and preclinical programs.
Expertise Areas
- Immuno-oncology therapeutic development
- Bispecific and fusion protein therapeutics
- Clinical trial management (Phase 1/2a)
- Biologics discovery and cell-line development
Key Technologies
- High-throughput protein screening
- Modular assembly of bispecific and fusion proteins
- Combinatorial library selection
- Mammalian cell-line development for biologics
News & Updates
GI Innovation and its sister company GI Biome have been selected as semi-finalists in the XPRIZE Healthspan competition, among over 600 teams from 58 countries. They are competing with a combination therapy of GI-102 and GIB-7 aimed at anti-aging.
GI Innovation has positioned itself as a formidable contender in the XPRIZE Healthspan competition, with clinical data supporting its anti-aging therapies, and has advanced to the finals.
GI Innovation and GI Biome are semi-finalists in the XPRIZE Healthspan competition, with a focus on anti-aging combination therapy involving GI-102 and GIB-7.
GI Innovation’s semi-finalist status in the XPRIZE Healthspan competition validates their anti-aging therapies, which could be a catalyst for longevity drug investments.
GI Innovation and GI Biome are semi-finalists in the XPRIZE Healthspan competition, with a combination therapy of GI-102 and GIB-7 targeting anti-aging.
GI Innovation and GI Biome are semi-finalists in the XPRIZE Healthspan competition, with a focus on anti-aging combination therapy involving GI-102 and GIB-7.
GI Innovation and its sister company GI Biome have been selected as semi-finalists in the XPRIZE Healthspan competition, among over 600 teams from 58 countries. They are competing with a combination therapy of GI-102 and GIB-7 aimed at anti-aging.
GI Innovation has positioned itself as a formidable contender in the XPRIZE Healthspan competition, with clinical data supporting its anti-aging therapies, and has advanced to the finals.
GI Innovation and GI Biome are semi-finalists in the XPRIZE Healthspan competition, with a focus on anti-aging combination therapy involving GI-102 and GIB-7.
GI Innovation’s semi-finalist status in the XPRIZE Healthspan competition validates their anti-aging therapies, which could be a catalyst for longevity drug investments.
GI Innovation and GI Biome are semi-finalists in the XPRIZE Healthspan competition, with a combination therapy of GI-102 and GIB-7 targeting anti-aging.
GI Innovation and GI Biome are semi-finalists in the XPRIZE Healthspan competition, with a focus on anti-aging combination therapy involving GI-102 and GIB-7.